Warning: fopen(/home/virtual/pediatrics/journal/upload/ip_log/ip_log_2023-06.txt) [function.fopen]: failed to open stream: Permission denied in /home/virtual/pediatrics/journal/ip_info/view_data.php on line 82

Warning: fwrite(): supplied argument is not a valid stream resource in /home/virtual/pediatrics/journal/ip_info/view_data.php on line 83
Montelukast as an add-on therapy in bronchopulmonary dysplasia

Korean Journal of Pediatrics 2009;52(2):181-186.
Published online February 15, 2009.
Montelukast as an add-on therapy in bronchopulmonary dysplasia
He Min Kim, Ji Eun Song, Soon Min Lee, Min Soo Park, Kook In Park, Ran Namgung, Chul Lee
Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea
기관지폐 이형성증의 추가 치료제로서의 Montelukast
김혜민, 송지은, 이순민, 박민수, 박국인, 남궁란, 이철
연세대학교 의과대학 소아과학교실
Min Soo Park, Email: minspark@yumc.yonsei.ac.kr
: Inflammation plays a potential role in the pathogenesis of bronchopulmonary dysplasia (BPD). Strategies for preventing BPD include respiratory management, antioxidants, nutritional treatment, and others such as anti-inflammatory agents. We aimed to assess the safety, tolerability, and efficacy of montelukast (MK), a cysteinyl leukotriene 1 receptor antagonist, as an add-on therapy in BPD.
: In addition to currently available standard measures such as oxygen supplementation, bronchodilators, nutritional support, and/or diuretics, montelukast was administered to 15 preterm infants with BPD. MK was given orally (1 mg/ kg/d) for a mean period of 12 weeks. We compared safety and efficacy parameters with historical controls.
: All 15 patients survived, and no differences were found in the incidence of adverse reactions between the 2 groups. The ventilation index was significantly improved after 2 weeks in MK group compared with historical controls. There were no significant differences in other respiratory parameters (MAP, oxygen dependency, and ventilator dependency) between the groups, but the MK group showed trends of greater improvement.
: Administration of MK 1 mg/kg/d was well tolerated in preterm BPD patients as an add-on therapy. We demonstrated that after 2 weeks of MK administration of 1 mg/kg/d, MK had beneficial therapeutic effects on BPD patients as an add-on to the standard therapy. Further multicenter randomized controlled clinical trials are needed to confirm the efficacy and safety of MK as a useful supplement to standard therapy for BPD patients.
Key Words: Bronchopulmonary dysplasia, Montelukast, Safety, Efficiency

METRICS Graph View
  • 3,453 View
  • 74 Download

Close layer
prev next